India's Eris Lifesciences launches a generic semaglutide priced at $13.8 per month

LootboxPhobia · 2026-03-20T13:43:57+00:00

India's Eris Lifesciences company has launched a generic semaglutide drug called Sundae, with a minimum dose priced at 1,290 rupees per month. The product is used for diabetes treatment, with a pen injector version expected to launch in April at a lower price. The drug is 88% cheaper than Novo Nordisk's Wegovy.

LootboxPhobia

2026-03-20 13:43:57

Abstract generation in progress

Investing.com - India’s Eris Lifesciences launched one of the most affordable generic versions of semaglutide on Friday, with a starting price of ₹1,290 ($13.8) per month for the lowest dose.

The company markets the product in India under the brand name Sundae for diabetes treatment. The minimum bottled dose of Sundae contains 2 mg of the active ingredient.

Eris’s partner in semaglutide distribution, Natco Pharma, priced the 2 mg minimum dose at ₹1,290 per month.

Eris plans to launch a pen-injector version of Sundae in April, offering three doses. The lowest 2 mg dose will cost ₹4,000 per month, while the highest 8 mg dose will be priced at ₹4,500 per month.

The company is one of dozens of Indian pharmaceutical companies launching generic semaglutide, as the patent held by Danish drugmaker Novo Nordisk for semaglutide expires on March 20. Larger competitors like Dr. Reddy’s are expected to launch their versions on Saturday.

On a monthly basis, Sundae’s 2 mg dose is 88% cheaper than Novo Nordisk’s Wegovy and 91% cheaper than Eli Lilly’s Mounjaro in the U.S.

This article was translated with the help of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes